This article is more than 5 years old. Information may no longer be current.
ACIP: HPV vaccination recommended for 11- to 12-year-old boys
Click Here to Manage Email Alerts
The CDC's Advisory Committee on Immunization Practices approved a routine recommendation in favor of administering the quadrivalent HPV vaccine for boys aged 11 to 12 years. The vote was 13-0 with one abstention.
Committee members decided that the vaccine (Gardasil, Merck) was safe, efficacious and cost-effective enough to warrant routine usage in this population. The recommendation issued in 2009 was permissive, meaning providers could give the vaccine to boys, but it was not routinely administered. This change would put the HPV vaccine into the regular vaccination schedule. The three-vaccination series can start as early as age 9 years.
"The committee recommended that routine vaccination of males aged 11 or 12 years with three doses of quadrivalent vaccine be given to prevent HPV infection and HPV-related disease," Anne Schuchat, MD, director of the CDC's National Center for Immunization and Respiratory Diseases, said in a phone call with reporters. "Boys and young men 13 to 21 years of age who have not already received the vaccine should be vaccinated."
Insurance companies typically cover HPV vaccine in boys, but that is not necessarily the case for a permissive recommendation, according to Schuchat, who said a routine recommendation for a vaccine usually translates into coverage without co-pays.
According to the committee, in extending the quadrivalent vaccine to young men, the vaccine was 89% effective against genital warts and 75% effective against precancerous anal intraepithelial neoplasia. Schuchat said the number of girls receiving vaccinations has been disappointing, and there is hope that vaccinating boys will protect both young women and young men.
"HPV vaccination for males offers an opportunity to decrease the burden of HPV-related disease in both males and females," Schuchat said. "So in addition to providing direct benefit to boys by preventing future genital warts or anal cancer, there's the potential that vaccinating boys will reduce the spread of HPV from males to females and reduce some of the HPV-related burden women suffer from."
About 20 million Americans currently have an HPV infection. According to the CDC, an estimated 7,080 men and 14,720 women develop cancers associated with HPV types 16 and 18 every year. An estimated 80% of anal cancers, 65% of vaginal cancers, 50% of vulvar cancers, 35% of penile cancers and nearly all cervical cancers are HPV-related. Roughly 60% of oropharyngeal cancers are associated with HPV, and HPV-related disease costs an estimated $8 billion annually.
Committee staff said vaccinating boys aged 11 to 12 years would cost $24,000 to $62,000 per quality-adjusted life year and would become more expensive per quality-adjusted life year as more girls are vaccinated.
The recommendation will now go to the full CDC. Schuchat said the agency will likely vote on the recommendation in a few months. – by Jason Harris
 |
Follow InfectiousDiseaseNews.com on Twitter. |